-
公开(公告)号：US11498928B2
公开(公告)日：2022-11-15
申请号：US17049100
申请日：2020-01-17
申请人： ASCENTAGE PHARMA (SUZHOU) CO., LTD. , THE REGENTS OF THE UNIVERSITY OF MICHIGAN , ASCENTAGE PHARMA GROUP CORP LIMITED
发明人： Jianyong Chen , Yunlong Zhou , Guozhi Tang , Chengzhe Wu , Leilei Zhao , Lingling Jiao , Binghua Sheng , Shaomeng Wang , Chao-Yie Yang , Hao Chen , Wenliang Hu , Yu Jing
IPC分类号： C07D513/20 , C07D515/20 , C07D498/08 , A61K31/553 , A61P35/00 , C07D513/10 , C07D519/00
摘要： Provided are compounds represented by Formula (I-A) and the pharmaceutically acceptable salts and solvates thereof, wherein R8, R9a, R9b, R9c, R9d, X, Y, Z, Z1, W, and (aa) are as defined as set forth in the specification. Provided are also compounds of Formula (I-A) for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
-
公开(公告)号：US20220340595A1
公开(公告)日：2022-10-27
申请号：US17047423
申请日：2019-11-20
申请人： ASCENTAGE PHARMA (SUZHOU) CO., LTD. , THE REGENTS OF THE UNIVERSITY OF MICHIGAN , ASCENTAGE PHARMA GROUP CORP LIMITED
发明人： Hao Chen , Wenming Chen , Chao Li , Dongbo Li , Yu Jing , Guozhi Tang , Yunlong Zhou , Shaomeng Wang , Chao-Yie Yang
IPC分类号： C07D515/22 , A61P35/00
摘要： Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, R1h, L2, L3, #, #, # are as defined as set forth in the re) specification. Disclosed is compound of formula I for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
-
公开(公告)号：US11691989B2
公开(公告)日：2023-07-04
申请号：US17047423
申请日：2019-11-20
申请人： ASCENTAGE PHARMA (SUZHOU) CO., LTD. , THE REGENTS OF THE UNIVERSITY OF MICHIGAN , ASCENTAGE PHARMA GROUP CORP LIMITED
发明人： Hao Chen , Wenming Chen , Chao Li , Dongbo Li , Yu Jing , Guozhi Tang , Yunlong Zhou , Shaomeng Wang , Chao-Yie Yang
IPC分类号： C07D497/22 , C07D515/22 , C07D231/12 , A61K31/395 , A61P35/00
CPC分类号： C07D515/22 , A61P35/00
摘要： Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, R1h, L2, L3, #, #, # are as defined as set forth in the re) specification. Disclosed is compound of formula I for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
-
公开(公告)号：US20210340158A1
公开(公告)日：2021-11-04
申请号：US17049100
申请日：2020-01-17
申请人： ASCENTAGE PHARMA (SUZHOU) CO., LTD. , THE REGENTS OF THE UNIVERSITY OF MICHIGAN , ASCENTAGE PHARMA GROUP CORP LIMITED
发明人： Jianyong Chen , Yunlong Zhou , Guozhi Tang , Chengzhe Wu , Leilei Zhao , Lingling Jiao , Binghua Sheng , Shaomeng Wang , Chao-Yie Yang , Hao Chen , Wenliang Hu , Yu Jing
IPC分类号： C07D513/20 , C07D513/10 , C07D519/00 , A61P35/00
摘要： Provided are compounds represented by Formula (I-A) and the pharmaceutically acceptable salts and solvates thereof, wherein R8, R9a, R9b, R9c, R9d, X, Y, Z, Z1, W, and (aa) are as defined as set forth in the specification. Provided are also compounds of Formula (I-A) for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
-
公开(公告)号：US20220396587A1
公开(公告)日：2022-12-15
申请号：US17048688
申请日：2020-01-22
申请人： ASCENTAGE PHARMA (SUZHOU) CO., LTD. , THE REGENTS OF THE UNIVERSITY OF MICHIGAN , ASCENTAGE PHARMA GROUP CORP LIMITED
发明人： Guozhi Tang , Dongbo Li , Liugen Li , Xianchan Zha , Wenming Chen , Shaomeng Wang , Chao-Yie Yang
IPC分类号： C07D515/22 , C07D497/22 , A61P35/00
摘要： Provided are compounds represented by Formula IA: (IA), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, L1, L2, L3, X, A, B and C are as defined as set forth in the specification. Also provided compounds of Formula IA for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
-
公开(公告)号：US20210230174A1
公开(公告)日：2021-07-29
申请号：US17200342
申请日：2021-03-12
发明人： CHAO LI , Guozhi Tang , Jianyong Chen , Lingling Jiao , Liugen Li
IPC分类号： C07D491/107 , C07D487/04 , C07D403/14 , C07D519/00 , C07D471/10 , C07D495/10 , A61P35/00
摘要： The present disclosure provides compounds represented by Formula I: wherein R3, A, A1, A2, A3, E, E1, E2, L, Q, Z, and are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Formula I are KRAS inhibitors and are thus useful to treat cancer and other diseases.
-
公开(公告)号：US11312724B2
公开(公告)日：2022-04-26
申请号：US17200342
申请日：2021-03-12
发明人： Chao Li , Guozhi Tang , Jianyong Chen , Lingling Jiao , Liugen Li
IPC分类号： C07D491/107 , C07D487/04 , C07D403/14 , A61P35/00 , C07D471/10 , C07D495/10 , C07D519/00
摘要： The present disclosure provides compounds represented by Formula I: wherein R3, A, A1, A2, A3, E, E1, E2, L, Q, Z, and are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Formula I are KRAS inhibitors and are thus useful to treat cancer and other diseases.
-
公开(公告)号：US11987575B2
公开(公告)日：2024-05-21
申请号：US17262586
申请日：2020-07-29
发明人： Yunlong Zhou , Guozhi Tang , Chao Li , Fang Liu , Yu Jing , Renlin Wang
IPC分类号： C07D403/04 , A61P35/02 , C07D209/94 , C07D401/04 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D495/04
CPC分类号： C07D403/04 , A61P35/02 , C07D209/94 , C07D401/04 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D495/04
摘要： The present disclosure provides compounds represented by Formula I, or an enantiomer or diastereomer, or a pharmaceutically acceptable salt thereof, wherein X, Y, Z, L, Ar, R1, R2, R3 R4, R5, R6, m, and p are defined herein. Compounds of Formula I are BCR-ABL inhibitors. BCR-ABL inhibitors are useful for the treatment of cancer and other diseases.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.028 秒)
